Medical Cannabis Rescheduling Shifts Consumer Sentiment Toward the Trump Administration
A quarterly presidential approval tracking poll conducted by NuggMD and Marijuana Moment from May 7‑26 2025 surveyed 484 cannabis consumers in states with legal markets. The results show that 73 percent of respondents now approve or strongly approve of the administration’s cannabis actions, a dramatic increase from just 6 percent in the last quarter of 2025, prior to the executive order directing officials to finalize rescheduling.
The survey also measured support for the specific policy shift: 86 percent favor moving medical cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), while 10 percent oppose it and 4 percent have no opinion. According to Andrew Graham, head of communications at NuggMD, the net approval figures have reversed over the past six months, reflecting a 115‑percent swing in sentiment.
If the administration pursued broader federal legalisation of cannabis, 61 percent of consumers said they would support it “much more,” and an additional 12 percent would support it “a bit more.”
Consumer Sentiment on Medical Cannabis Rescheduling
The same NuggMD‑Marijuana Moment poll indicates that the rescheduling initiative itself enjoys broad backing. Eighty‑six percent of respondents favor the reform, underscoring a clear consumer preference for changing the federal classification of medical cannabis.
Regulatory Framework and Legal Challenges
The reclassification of medical cannabis under the CSA is an administrative process, but it has encountered legal resistance. Three Republican state attorneys general—from Indiana, Nebraska, and Louisiana—filed a lawsuit in the U.S. Court of Appeals for the District of Columbia Circuit, arguing that the agency action was improperly promulgated, procedurally flawed, exceeds statutory authority, and is arbitrary, capricious, and an abuse of discretion.
This case has been consolidated with a separate challenge brought by the prohibitionist organisation Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA). The Department of Justice, the Drug Enforcement Administration (DEA), Blanche, and DEA Administrator Terrance Cole are named as defendants in the consolidated suits.
A separate federal judge recently dismissed litigation filed by SAM that contested an administration initiative to cover up to US $500 worth of hemp‑derived products annually for eligible Medicare patients.
Congressional Opposition to Rescheduling
In a related development, a House committee voted earlier this month to prevent federal officials from taking further steps to implement cannabis rescheduling. The vote highlights ongoing debate within Congress about the federal government’s approach to cannabis policy, even as the administrative process continues.
Outlook for Medical Cannabis Rescheduling
The current landscape features a notable shift in public support alongside active legal and legislative opposition. An upcoming administrative hearing is expected to provide further clarity on the implementation and scope of the reclassification. Stakeholders in the medical cannabis sector are monitoring these developments closely, as the outcomes will affect regulatory compliance and market dynamics for medical cannabis products.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid‑derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
For the original source, see: Here
